CN108602782B - N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物 - Google Patents

N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物 Download PDF

Info

Publication number
CN108602782B
CN108602782B CN201680075353.5A CN201680075353A CN108602782B CN 108602782 B CN108602782 B CN 108602782B CN 201680075353 A CN201680075353 A CN 201680075353A CN 108602782 B CN108602782 B CN 108602782B
Authority
CN
China
Prior art keywords
degrees
cancer
salt
theta
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680075353.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108602782A (zh
Inventor
P·琼斯
迈克尔·J·索思
詹森·B·伯克
乐康
刘刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN108602782A publication Critical patent/CN108602782A/zh
Application granted granted Critical
Publication of CN108602782B publication Critical patent/CN108602782B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680075353.5A 2015-12-22 2016-12-21 N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物 Active CN108602782B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271018P 2015-12-22 2015-12-22
US62/271,018 2015-12-22
PCT/US2016/068149 WO2017112831A1 (en) 2015-12-22 2016-12-21 Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide

Publications (2)

Publication Number Publication Date
CN108602782A CN108602782A (zh) 2018-09-28
CN108602782B true CN108602782B (zh) 2022-06-17

Family

ID=59065954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680075353.5A Active CN108602782B (zh) 2015-12-22 2016-12-21 N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物

Country Status (14)

Country Link
US (4) US10150753B2 (ru)
EP (1) EP3394039A4 (ru)
JP (1) JP6976248B2 (ru)
KR (1) KR20180095677A (ru)
CN (1) CN108602782B (ru)
AU (1) AU2016378746B2 (ru)
BR (1) BR112018012660B1 (ru)
CA (1) CA3009355A1 (ru)
IL (1) IL260178B2 (ru)
MX (1) MX2018007143A (ru)
RU (1) RU2018124266A (ru)
SG (1) SG11201804664XA (ru)
WO (1) WO2017112831A1 (ru)
ZA (1) ZA201804843B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016030730B1 (pt) 2014-07-03 2023-05-02 Board Of Regents, The University Of Texas System Composto
US10125128B2 (en) 2015-06-30 2018-11-13 Board Of Regents, The University Of Texas System GLS1 inhibitors for treating disease
AU2016378746B2 (en) 2015-12-22 2021-05-20 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
EP3697764A4 (en) 2017-10-18 2021-07-21 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY
CN116023375A (zh) * 2021-10-25 2023-04-28 成都苑东生物制药股份有限公司 一种杂环类衍生物、其制备方法及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015101957A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel glutaminase inhibitors
CN107074805A (zh) * 2014-07-03 2017-08-18 德州大学系统董事会 用于治疗疾病的gls1抑制剂

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES498337A0 (es) 1980-01-07 1982-06-01 Nyegaard & Co As Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas
EP0218753B1 (en) 1985-10-10 1989-08-09 Agfa-Gevaert N.V. Image-recieving element for the silver salt diffusion transfer reversal process
AU6979091A (en) 1989-12-22 1991-07-24 Upjohn Company, The Pyridinones useful as antiatherosclerotic agents
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
JP4422796B2 (ja) 1995-07-21 2010-02-24 タクティカル セラピューティクス インコーポレイテッド アミノイミダゾールカルボキサミドおよび５−アミノ、または置換アミノ１，２，３−トリアゾールの塩による癌の治療および阻止
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20100255117A1 (en) 2007-04-06 2010-10-07 The Johns Hopkins University Methods and compositions for the treatment of cancer
PT2247592E (pt) 2008-02-25 2011-11-03 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
NZ595280A (en) 2009-02-27 2013-11-29 Enanta Pharm Inc Hepatitis c virus inhibitors
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
WO2011089995A1 (ja) 2010-01-21 2011-07-28 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
EP2782570B1 (en) 2011-11-21 2019-09-18 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
WO2014081925A1 (en) 2012-11-21 2014-05-30 Agios Pharmaceuticals, Inc. Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP2952096B1 (en) 2013-01-30 2018-04-04 Sumitomo Chemical Company, Limited Amide compound, an arthropod pest control agent and a method for controlling arthropod pest
TW201500356A (zh) 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
US20160058759A1 (en) 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
US20160002248A1 (en) 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016004417A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
US10125128B2 (en) 2015-06-30 2018-11-13 Board Of Regents, The University Of Texas System GLS1 inhibitors for treating disease
AU2016378746B2 (en) 2015-12-22 2021-05-20 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
EP3697764A4 (en) 2017-10-18 2021-07-21 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015101957A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel glutaminase inhibitors
CN107074805A (zh) * 2014-07-03 2017-08-18 德州大学系统董事会 用于治疗疾病的gls1抑制剂

Also Published As

Publication number Publication date
RU2018124266A (ru) 2020-01-23
US20210206745A1 (en) 2021-07-08
JP2019502663A (ja) 2019-01-31
IL260178B2 (en) 2023-05-01
WO2017112831A1 (en) 2017-06-29
US20190144425A1 (en) 2019-05-16
US10150753B2 (en) 2018-12-11
MX2018007143A (es) 2018-11-29
CN108602782A (zh) 2018-09-28
US20170174661A1 (en) 2017-06-22
BR112018012660B1 (pt) 2023-12-19
EP3394039A4 (en) 2019-06-12
EP3394039A1 (en) 2018-10-31
JP6976248B2 (ja) 2021-12-08
ZA201804843B (en) 2019-09-25
AU2016378746A1 (en) 2018-06-28
RU2018124266A3 (ru) 2020-03-25
IL260178B1 (en) 2023-01-01
US11603365B2 (en) 2023-03-14
BR112018012660A2 (pt) 2018-12-04
AU2016378746B2 (en) 2021-05-20
SG11201804664XA (en) 2018-07-30
US10899740B2 (en) 2021-01-26
KR20180095677A (ko) 2018-08-27
CA3009355A1 (en) 2017-06-29
IL260178A (en) 2018-07-31
US20230250081A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CN108602782B (zh) N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物
US11713313B2 (en) GLS1 inhibitors for treating disease
ES2788449T3 (es) Inhibidores de GLS1 para tratar enfermedades
AU2018285131B2 (en) Heteroaromatic compounds as Vanin inhibitors
WO2016004417A1 (en) Gls1 inhibitors for treating disease
US20160060260A1 (en) Bromodomain inhibitors for treating disease
NZ743251A (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
WO2023230612A1 (en) Heterocyclic pad4 inhibitors
WO2023230609A1 (en) Heterocyclic pad4 inhibitors
IL301707A (en) Imidazopiperazine inhibitors of transcription-activating proteins
NZ738078A (en) Mct4 inhibitors for treating disease
BR112017028309B1 (pt) Composto e composição

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260678

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant